Tue, 25 May|
Using RWD for drug approval
This is an internal CONNECT meeting, hosted by Working Group 4.
Time & Location
25 May 2021, 15:30 – 16:45
About the event
Topics and speakers:
RWD in regulatory processes, hurdles and possibilities from the Regulatory Authority perspective
Anja Schiel, Special Adviser and Lead Methodologist in Regulatory and Pharmacoeconomic Statistics, Norwegian Medicines Agency
RWD: The perspective from a Pharmaceutical company
Leah Burns, Director, WW HEOR, RWE Strategy, Bristol Myers Squibb, USA
Please note: This is a CONNECT internal, closed meeting. CONNECT Partners receive a personal calendar invite / email invitation. If you are a CONNECT Partners and haven't received an invite, please contact Jutta Heix (firstname.lastname@example.org).